Cue Biopharma Statistics
Total Valuation
Cue Biopharma has a market cap or net worth of $37.03 million. The enterprise value is $6.16 million.
| Market Cap | 37.03M |
| Enterprise Value | 6.16M |
Important Dates
The next estimated earnings date is Wednesday, August 7, 2024, after market close.
| Earnings Date | Aug 7, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Cue Biopharma has 48.64 million shares outstanding. The number of shares has increased by 10.78% in one year.
| Shares Outstanding | 48.64M |
| Shares Change (YoY) | +10.78% |
| Shares Change (QoQ) | +4.81% |
| Owned by Insiders (%) | 0.68% |
| Owned by Institutions (%) | 34.29% |
| Float | 45.38M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 5.28 |
| Forward PS | 8.00 |
| PB Ratio | 1.23 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.88 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.47, with a Debt / Equity ratio of 0.43.
| Current Ratio | 2.47 |
| Quick Ratio | 2.50 |
| Debt / Equity | 0.43 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -38.47 |
Financial Efficiency
Return on equity (ROE) is -128.30% and return on invested capital (ROIC) is -119.52%.
| Return on Equity (ROE) | -128.30% |
| Return on Assets (ROA) | -77.60% |
| Return on Capital (ROIC) | -119.52% |
| Revenue Per Employee | $132,453 |
| Profits Per Employee | -$942,849 |
| Employee Count | 53 |
| Asset Turnover | 0.11 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -83.08% in the last 52 weeks. The beta is 1.95, so Cue Biopharma's price volatility has been higher than the market average.
| Beta (5Y) | 1.95 |
| 52-Week Price Change | -83.08% |
| 50-Day Moving Average | 1.40 |
| 200-Day Moving Average | 2.04 |
| Relative Strength Index (RSI) | 25.30 |
| Average Volume (20 Days) | 605,514 |
Short Selling Information
The latest short interest is 4.74 million, so 9.75% of the outstanding shares have been sold short.
| Short Interest | 4.74M |
| Short Previous Month | 4.49M |
| Short % of Shares Out | 9.75% |
| Short % of Float | 10.45% |
| Short Ratio (days to cover) | 11.00 |
Income Statement
In the last 12 months, Cue Biopharma had revenue of $7.02 million and -$49.97 million in losses. Loss per share was -$1.07.
| Revenue | 7.02M |
| Gross Profit | 7.02M |
| Operating Income | -51.44M |
| Pretax Income | -49.97M |
| Net Income | -49.97M |
| EBITDA | -44.60M |
| EBIT | -48.71M |
| Loss Per Share | -$1.07 |
Balance Sheet
The company has $43.87 million in cash and $13.00 million in debt, giving a net cash position of $30.87 million or $0.63 per share.
| Cash & Cash Equivalents | 43.87M |
| Total Debt | 13.00M |
| Net Cash | 30.87M |
| Net Cash Per Share | $0.63 |
| Equity (Book Value) | 30.04M |
| Book Value Per Share | 0.62 |
| Working Capital | 26.58M |
Cash Flow
In the last 12 months, operating cash flow was -$38.91 million and capital expenditures -$55,000, giving a free cash flow of -$38.97 million.
| Operating Cash Flow | -38.91M |
| Capital Expenditures | -55,000 |
| Free Cash Flow | -38.97M |
| FCF Per Share | -$0.79 |
Margins
Gross margin is 100.00%, with operating and profit margins of -732.71% and -711.84%.
| Gross Margin | 100.00% |
| Operating Margin | -732.71% |
| Pretax Margin | -711.84% |
| Profit Margin | -711.84% |
| EBITDA Margin | -635.28% |
| EBIT Margin | -693.80% |
| FCF Margin | -555.09% |
Dividends & Yields
Cue Biopharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -10.78% |
| Shareholder Yield | -10.78% |
| Earnings Yield | -134.94% |
| FCF Yield | -105.22% |
Analyst Forecast
The average price target for Cue Biopharma is $8.00, which is 950.83% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $8.00 |
| Price Target Difference | 950.83% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | 113.75% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Cue Biopharma has an Altman Z-Score of -9.46 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -9.46 |
| Piotroski F-Score | 3 |